Generate Biomedicines executive reports 5.2% stake

Generate Biomedicines, Inc. executive Michael Nally reported beneficial ownership of 6,919,051 shares of Common Stock, representing 5.2% of the class as of March 31, 2026.

Rhea-AI Filing Summary

Generate Biomedicines, Inc. executive Michael Nally reported beneficial ownership of 6,919,051 shares of Common Stock, representing 5.2% of the class as of March 31, 2026. The filing cites 128,192,484 shares outstanding as of March 31, 2026. The reported stake includes 4,029,897 shares underlying stock options exercisable within 60 days and several record holdings across trusts and a GRAT. The statement is a beneficial ownership disclosure under Schedule 13G and is signed by Michael Nally on May 15, 2026.

Insights

Corporate Governance Analyst

Executive reports a 5.2% beneficial stake including exercisable options.

The filing shows Michael Nally beneficially owns 6,919,051 shares of Common Stock, based on 128,192,484 shares outstanding as of March 31, 2026. The position aggregates direct holdings, trust/GRAT record shares, and 4,029,897 options exercisable within 60 days.

The economic and voting power is reported as sole for all 6,919,051 shares. Future disclosures may reflect any exercises or dispositions; timing and cash‑flow treatment for any option exercises are not stated in the excerpt.

Key Figures

Beneficial ownership: 6,919,051 shares Percent of class: 5.2% Shares outstanding: 128,192,484 shares +4 more

7 metrics

Beneficial ownership 6,919,051 shares Beneficially owned as of <date>March 31, 2026</date>

Percent of class 5.2% Based on 128,192,484 shares outstanding as of <date>March 31, 2026</date>

Shares outstanding 128,192,484 shares Shares outstanding as of <date>March 31, 2026</date>

Options exercisable 4,029,897 shares Underlying stock options exercisable within 60 days of <date>March 31, 2026</date>

Direct record holdings 572,707 shares Shares held of record by the Reporting Person

MTN 2024 GST Trust record 1,316,654 shares Shares held of record by the MTN 2024 GST Trust

MTN 2024 GRAT record 999,793 shares Shares held of record by the MTN 2024 GRAT

Key Terms

beneficially owned, stock options exercisable within 60 days, Schedule 13G

3 terms

beneficially owned regulatory

"The Reporting Person may be deemed to be the beneficial owner of 6,919,051 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

stock options exercisable within 60 days financial

"4,029,897 shares underlying stock options exercisable within 60 days"

Schedule 13G regulatory

"This statement is filed on behalf of Michael Nally (the "Reporting Person")."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What stake does Michael Nally report in Generate Biomedicines (GENB)?

Michael Nally reports beneficial ownership of 6,919,051 shares, equal to 5.2% of the outstanding common stock as of March 31, 2026. The figure aggregates direct shares, trust/GRAT holdings, and exercisable options.

How many shares outstanding does the filing cite for GENB?

The filing cites 128,192,484 shares outstanding as of March 31, 2026, which is the basis for the reported 5.2% beneficial ownership percentage disclosed by Michael Nally.

How much of the reported stake is exercisable options?

The filing states 4,029,897 shares are underlying stock options exercisable within 60 days of March 31, 2026. These options are included in the reported beneficial ownership total of 6,919,051 shares.

Does Michael Nally report sole voting and dispositive power?

Yes. The filing reports Michael Nally has sole voting power and sole dispositive power over 6,919,051 shares, with 0 shared voting or dispositive power reported in the schedule.

When was the Schedule 13G signed for this disclosure?

The Schedule 13G is signed by Michael Nally and dated May 15, 2026. The ownership snapshot within the filing is anchored to March 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 08:33 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Generate Biomedicines, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

370920100

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 370920100

1

Names of Reporting Persons

Nally Michael

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,919,051.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,919,051.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,919,051.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Generate Biomedicines, Inc.
(b)	Address of issuer's principal executive offices: 101 South Street, Suite 900, Somerville, MA 02143
Item 2.
(a)	Name of person filing: This statement is filed on behalf of Michael Nally (the "Reporting Person").
(b)	Address or principal business office or, if none, residence: c/o Generate Biomedicines, Inc., 101 South Street, Suite 900, Somerville, MA 02143.
(c)	Citizenship: The Reporting Person is a citizen of the United States.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP Number(s): 370920100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The ownership information below represents beneficial ownership of Common Stock of the Issuer as of March 31, 2026, based upon 128,192,484 shares of Common Stock outstanding as of March 31, 2026, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026. The Reporting Person may be deemed to be the beneficial owner of 6,919,051 shares of Common Stock, which includes: (i) 572,707 shares of Common Stock held of record by the Reporting Person; (ii) 1,316,654 shares of Common Stock held of record by the MTN 2024 GST Trust; (iii) 999,793 shares of Common Stock held of record by the MTN 2024 GRAT; and (iv) 4,029,897 shares of Common Stock underlying stock options exercisable within 60 days of March 31, 2026 by the Reporting Person.
(b)	Percent of class: 5.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6,919,051
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6,919,051
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nally Michael

Signature:	/s/ Michael Nally
Name/Title:	Michael Nally
Date:	05/15/2026